ArticleFrontiers in oncology2019
A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 67 citations in OpenAlex.
- First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.Signal transduction and targeted therapy · 2025Trial
- CTLA4 genetic variants influence immune regulation and susceptibility of HPV associated cervical cancer.Discover oncology · 2025Review
- LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity.Nature immunology · 2024Article
- Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma.Biomolecules & biomedicine · 2023Article
- Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.Molecular cancer · 2023Review
- Expression and Clinical Significance ofInternational journal of general medicine · 2023Article
- Natural killer cell profiles in recurrent pregnancy loss: Increased expression and positive associations with TACTILE and LILRB1.American journal of reproductive immunology (New York, N.Y. : 1989) · 2022Article
- Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.Cancer treatment reviews · 2022Review
- TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.Journal for immunotherapy of cancer · 2022Review
- Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.Cells · 2022Article
- Synthetic receptors for logic gated T cell recognition and function.Current opinion in immunology · 2022Review
- Update in TIGIT Immune-Checkpoint Role in Cancer.Frontiers in oncology · 2022Review
- Emergence of the CD226 Axis in Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody.Scientific reports · 2021Article
- The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives.Journal of clinical medicine · 2021Review
- Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.Molecular therapy oncolytics · 2021Review
- PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 10 institutions in 2 countries.
Xi LiKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Rouzheng WangKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Peiwen FanKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Xuan YaoNuffield Department of Medicine (NDM), Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), University of Oxford, Oxford, United Kingdom.
Ling QinBeijing You'an Hospital, Capital Medical University, Beijing, China.
Yanchun PengNuffield Department of Medicine (NDM), Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), University of Oxford, Oxford, United Kingdom.
Miaomiao MaKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Neil AsleySingle Cell Genomics Facility, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Xuimei ChangKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Yaning FengKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Yunhui HuKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Yonghong ZhangBeijing You'an Hospital, Capital Medical University, Beijing, China.
Chris LiChina R&D, Janssen Pharmaceuticals, Shanghai, China.
Gregory FanningChina R&D, Janssen Pharmaceuticals, Shanghai, China.
Stephanie JonesOxford Radcliffe Biobank, Department of Cellular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Clare VerrillNuffield Department of Surgical Sciences, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
David Maldonado-PerezNuffield Department of Surgical Sciences, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Paul SoppFlow Cytometry Facility, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Craig WaughFlow Cytometry Facility, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Stephen TaylorBioinformatics Team, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Simon McgowanBioinformatics Team, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Vincenzo CerundoloNuffield Department of Medicine (NDM), Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), University of Oxford, Oxford, United Kingdom.
Christopher ConlonNuffield Department of Medicine (NDM), Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), University of Oxford, Oxford, United Kingdom.
Andrew McMichaelNuffield Department of Medicine (NDM), Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), University of Oxford, Oxford, United Kingdom.
Shichun LuChina Military General Hospital, Beijing, China.
Xiyan WangKey Laboratory of Tumor Immunology and Radiation Therapy, Third Affiliated Hospital, Xinjiang Tumor Hospital, Chinese Academy of Medical Sciences (CAMS), Xinjiang Medical University, Ürümqi, China.
Ning LiBeijing You'an Hospital, Capital Medical University, Beijing, China.
Tao DongNuffield Department of Medicine (NDM), Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), University of Oxford, Oxford, United Kingdom.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNUniversity of Oxford · GBAcademy of Medical Sciences · GBBeijing YouAn Hospital · CNMRC Weatherall Institute of Molecular Medicine · GBMRC Human Immunology Unit · GBTumor Hospital of Xinjiang Medical University · CNChinese People's Liberation Army · CNOxford University Hospitals NHS Trust · GBXinjiang Medical University · CN
Funding
Cancer Research UK 11331Cancer Research UK 17722Medical Research Council G0501975Medical Research Council G0600520Medical Research Council G0800158Medical Research Council G1000800Medical Research Council G1001046Medical Research Council MC_PC_15002Medical Research Council MC_PC_15065Medical Research Council MC_U137884181Medical Research Council MC_UU_00008/1Medical Research Council MC_UU_12010/1Medical Research Council MR/K01577X/1Medical Research Council MR/K021222/1Medical Research Council MR/L018942/1
Abstract
PubMed holds no abstract for this paper.
Indexed as
combinatorial checkpoint blockadeinhibitory receptorT cellstumor-infiltrating lymphocytestumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.